Compound News and Research

RSS

New compound AMN107 may help treat some imatinib resistant cancer cases

As scientists uncover the precise molecular mechanisms that underlie effective cancer treatments, they gain invaluable insight into why predominantly successful treatments fail for some patients.

14 Feb 2005

Chronic nicotine exposure worsens some Alzheimer’s-related brain abnormalities

UCI researchers have determined that chronic nicotine exposure worsens some Alzheimer’s-related brain abnormalities, contradicting the common belief that nicotine can actually be used to treat the disease.

9 Feb 2005

Artemisinin could selectively kill cancer cells while leaving normal cells unharmed

Researchers at the University of Washington have blended the past with the present in the fight against cancer, synthesizing a promising new compound from an ancient Chinese remedy that uses cancer cells' rapacious appetite for iron to make them a target.

9 Feb 2005

Eat carrots to fight cancer

Scientists have given us another reason to eat carrots - a compound found in the popular root vegetable has been found to have an effect on the development of cancer.

8 Feb 2005

Breakthrough method in nanoparticle synthesis paves the way for new pharmaceutical and biomedical applications

The Institute of Bioengineering and Nanotechnology (IBN) has developed a novel method to simultaneously control the size and morphology of nanoparticles, which can be used in pharmaceutical synthesis and novel biomedical applications.

8 Feb 2005

Variation in a taste receptor gene influences taste sensitivity

Variation in a taste receptor gene influences taste sensitivity of children and adults, accounting for individual differences in taste preferences and food selection, report a team of researchers from the Monell Chemical Senses Center. In addition to genes, age and culture also contribute to taste preferences, at times overriding the influence of genetics.

7 Feb 2005

Compound, derived from a rare South American plant, stops the growth of human breast cancer cells

They started with a bare room and an idea. Now, after five years of painstaking, sophisticated tests, scientists at the University of Virginia Health System have discovered that a compound, derived from a rare South American plant, stops the growth of human breast cancer cells in laboratory cultures.

1 Feb 2005

Eleventh Edition of the Report on Carcinogens

The Department of Health and Human Services released its Eleventh Edition of the Report on Carcinogens today, adding seventeen substances to the growing list of cancer-causing agents, bringing the total to 246.

31 Jan 2005

Schering and Novartis agree on joint commercialization of novel cancer drug

Schering AG, Germany announced today that, following regulatory approvals, it will co-promote the novel oral angiogenesis inhibitor PTK787/ZK 222584 (PTK/ZK) for all oncology indications together with Novartis Pharma AG in Europe, North America and Japan. This agreement will enable both Schering and Novartis to maximize the compound's full potential.

25 Jan 2005

Monoclonal antibody therapeutics to fill vacuum left by ineffective conventional therapies

Currently, the limited efficacy of conventional therapies, especially in the case of several oncology and autoimmune and inflammatory disorders (AIID), is creating the need for safe and effective treatment alternatives.

25 Jan 2005

Breakthrough in identifying causes and treatment for degenerative neurological diseases

A new, high resolution x-ray scanning technique that can look inside a single brain tissue cell, is a major step forward in identifying the role of iron and other metals in degenerative neurological diseases such as Alzheimer’s and Parkinson’s.

24 Jan 2005

Organon’s compound, Org 24448, selected to test efficacy of cognitive dysfunction in schizophrenia

The National Institute of Mental Health (NIMH) sponsored network called Treatment Units for Research on Neurocognition in Schizophrenia (TURNS) has selected Organon’s compound, Org 24448, to undergo testing as part of its effort to facilitate the development of medications to enhance cognition in patients with schizophrenia.

24 Jan 2005

Strategic analysis of the European tissue sealants market

Although the USD 90 million European tissue sealants market is in the growth phase, the rate of growth is projected to be gradual due to sluggish technological advancements, the slow pace of collecting clinical evidence and unclear product demarcations. Moreover, while around 35 per cent of all internal surgical procedures offer the potential for sealants' use, their deployment has been limited to only a few procedures.

19 Jan 2005

Researchers have identified the cellular receptor for the JC virus

Researchers funded in part by the National Institute of Neurological Disorders and Stroke (NINDS) have identified the cellular receptor for the JC virus, which causes the fatal neurological disease progressive multifocal leukoencephalopathy (PML).

17 Jan 2005

Evaluation of BAY 43-9006 (Sorafenib) for pancreatic cancer

Oncologists from USC/Norris Comprehensive Cancer Center are running tests on a new pancreatic cancer drug that targets the cancer from two directions.

13 Jan 2005

Major partnership with National Institute of Allergy and Infectious Diseases for Narhex Life Sciences

Australian drug specialist Narhex Life Sciences, has announced a partnership with one of the world’s foremost US medical research centres to evaluate its protease inhibitor Nar DG 35 Prodrug for its activity against Hepatitis C and SARS viruses.

12 Jan 2005

Researchers to test new leukemia drug

Chronic myeloid leukemia (CML) is a malignant cancer of the blood that affects people of all ages. While treatment is available for most of these patients, approximately 20 percent of them do not respond to it. Researchers at McGill teaching hospitals will soon study the effects of a new alternative therapy.

12 Jan 2005

Research breakthrough in treatment of TB and MDR-TB

FASgen Inc.'s compound, FAS20013, has emerged from an intense multi-year program of pre-clinical studies that clearly validate its potential as an ideal new drug for the treatment of tuberculosis and MDR-TB, the disease caused by organisms that are resistant to the drugs now commonly used to treat TB. Initial clinical trials in both TB and MDR-TB are scheduled for later this year.

12 Jan 2005

Escalating demand for novel and effective therapeutic approaches underlines growing appeal of peptides

With a 30 per cent revenue share, Europe trails the United States as the second largest regional market for therapeutic peptides. The rising need for new therapeutic approaches combined with the potential of peptides as active pharmaceutical ingredients for effective drug formulation is contributing to rapid market development.

12 Jan 2005

Potential new therapies for cancer and bleeding disorders

Lexicon Genetics announced today that it has advanced two of its drug discovery programs into preclinical development in preparation for investigational new drug (IND) applications.

10 Jan 2005

Compound News and Research

New compound AMN107 may help treat some imatinib resistant cancer cases

Chronic nicotine exposure worsens some Alzheimer’s-related brain abnormalities

Artemisinin could selectively kill cancer cells while leaving normal cells unharmed

Eat carrots to fight cancer

Breakthrough method in nanoparticle synthesis paves the way for new pharmaceutical and biomedical applications

Variation in a taste receptor gene influences taste sensitivity

Compound, derived from a rare South American plant, stops the growth of human breast cancer cells

Eleventh Edition of the Report on Carcinogens

Schering and Novartis agree on joint commercialization of novel cancer drug

Monoclonal antibody therapeutics to fill vacuum left by ineffective conventional therapies

Breakthrough in identifying causes and treatment for degenerative neurological diseases

Organon’s compound, Org 24448, selected to test efficacy of cognitive dysfunction in schizophrenia

Strategic analysis of the European tissue sealants market

Researchers have identified the cellular receptor for the JC virus

Evaluation of BAY 43-9006 (Sorafenib) for pancreatic cancer

Major partnership with National Institute of Allergy and Infectious Diseases for Narhex Life Sciences

Researchers to test new leukemia drug

Research breakthrough in treatment of TB and MDR-TB

Escalating demand for novel and effective therapeutic approaches underlines growing appeal of peptides

Potential new therapies for cancer and bleeding disorders

Advancing therapeutic biopolymer development eBook

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring

Latest News